Budget impact of implementing platelet pathogen reduction into the Italian blood transfusion system

Americo Cicchetti, Silvia Coretti, Francesco Sacco, Paolo Rebulla, Alessandra Fiore, Filippo Rumi, Rossella Di Bidino, Luz Irene Urbina, Pietro Refolo, Dario Sacchini, Antonio Gioacchino Spagnolo, Emanuela Midolo, Giuseppe Marano, Blandina Farina, Ilaria Pati, Eva Veropalumbo, Simonetta Pupella, Giancarlo M. Liumbruno

Risultato della ricerca: Contributo in rivistaArticolo in rivista

11 Citazioni (Scopus)


Background. Despite improvements in blood donor selection and screening procedures, transfusion recipients can still develop complications related to infections by known and emerging pathogens. Pathogen reduction technologies (PRT) have been developed to reduce such risks. The present study, developed whithin a wider health technology assessment (HTA) process, was undertaken to estimate the costs of the continuing increase in the use of platelet PRT in Italy. Materials and methods. A multidisciplinary team was established to perform the HTA and conduct a budget impact analysis. Quantitative data on platelet use were derived from the 2015 national blood transfusion report and from the Italian Platelets Transfusion Assessment Study (IPTAS). The current national fee of 60 Euro per platelet PRT procedure was used to quantify the costs to the Italian National Health Service (INHS). The analysis adopts a 3-year time-frame. In order to identify the impact on budget we compared a scenario representing an increased use of PRT platelets over time with a control scenario in which standard platelets are used. Results. Progressive implementation of PRT for 20%, 40% and 66% of annual adult platelet doses could generate an increase in annual costs for the INHS amounting to approximately 7, 14 and 23 million Euros, respectively. Use of kits and devices suitable for the treatment of multiple adult platelet doses in one PRT procedure could lower costs. Discussion. In order to fully evaluate the societal perspective of implementing platelet PRT, the increase in costs must be balanced against the expected benefits (prevention of transfusion-transmissible infections, white cell inactivation, extension of platelet storage, discontinuation of pathogen detection testing). Further studies based on actual numbers of platelet transfusion complications and their societal cost at a local level are needed to see the full cost to benefit ratio of platelet PRT implementation in Italy, and to promote equal treatment for all citizens.
Lingua originaleEnglish
pagine (da-a)1-7
Numero di pagine7
RivistaBlood Transfusion
Stato di pubblicazionePubblicato - 2018


  • pathogen reduction technology
  • platelet transfusion
  • transfusion risks


Entra nei temi di ricerca di 'Budget impact of implementing platelet pathogen reduction into the Italian blood transfusion system'. Insieme formano una fingerprint unica.

Cita questo